Citigroup’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-14,900
Closed -$1.66M 5893
2024
Q3
$1.66M Buy
+14,900
New +$1.63M ﹤0.01% 2823
2021
Q1
Sell
-9,800
Closed -$1.62M 6839
2020
Q4
$1.62M Sell
9,800
-5,500
-36% -$819K ﹤0.01% 3063
2020
Q3
$2.18M Sell
15,300
-5,200
-25% -$645K ﹤0.01% 2575
2020
Q2
$2.26M Buy
20,500
+5,800
+39% +$641K ﹤0.01% 2680
2020
Q1
$1.47M Sell
14,700
-5,400
-27% -$698K ﹤0.01% 2794
2019
Q4
$3M Sell
20,100
-15,400
-43% -$2.1M ﹤0.01% 2537
2019
Q3
$4.55M Sell
35,500
-23,300
-40% -$3.12M ﹤0.01% 2038
2019
Q2
$8.38M Buy
58,800
+46,800
+390% +$6.29M 0.01% 1528
2019
Q1
$1.72M Sell
12,000
-46,600
-80% -$6.08M ﹤0.01% 2822
2018
Q4
$7.26M Buy
58,600
+46,600
+388% +$6.91M 0.01% 1509
2018
Q3
$2.02M Sell
12,000
-19,000
-61% -$3.27M ﹤0.01% 2739
2018
Q2
$5.34M Buy
31,000
+24,200
+356% +$3.96M ﹤0.01% 1777
2018
Q1
$1.03M Buy
6,800
+3,000
+79% +$440K ﹤0.01% 3220
2017
Q4
$512K Sell
3,800
-7,200
-65% -$999K ﹤0.01% 4069
2017
Q3
$1.61M Sell
11,000
-28,500
-72% -$4.31M ﹤0.01% 2895
2017
Q2
$6.14M Buy
39,500
+19,600
+98% +$3M 0.01% 1538
2017
Q1
$2.89M Buy
19,900
+6,800
+52% +$886K ﹤0.01% 2129
2016
Q4
$1.43M Sell
13,100
-5,500
-30% -$613K ﹤0.01% 3313
2016
Q3
$2.26M Sell
18,600
-600
-3% -$80.9K ﹤0.01% 2405
2016
Q2
$2.71M Buy
19,200
+2,500
+15% +$369K ﹤0.01% 2099
2016
Q1
$2.18M Buy
16,700
+7,500
+82% +$934K ﹤0.01% 2393
2015
Q4
$1.29M Sell
9,200
-800
-8% -$111K ﹤0.01% 2855
2015
Q3
$1.33M Buy
10,000
+4,700
+89% +$809K ﹤0.01% 2810
2015
Q2
$933K Buy
5,300
+4,600
+657% +$826K ﹤0.01% 3202
2015
Q1
$121K Buy
+700
New +$120K ﹤0.01% 4877
2014
Q4
Sell
-144,300
Closed -$23.2M 7207
2014
Q3
$23.2M Buy
+144,300
New +$22.2M 0.02% 719
2014
Q2
Sell
-15,000
Closed -$2.08M 7223
2014
Q1
$2.08M Buy
+15,000
New +$2.26M ﹤0.01% 2329
2013
Q3
Sell
-20,000
Closed -$1.38M 6889
2013
Q2
$1.38M Buy
+20,000
New +$1.22M ﹤0.01% 2642

Other funds holding JAZZ

Citigroup's JAZZ Position: Q1 2026 in Review

Citigroup increased its Jazz Pharmaceuticals (JAZZ) stake by 137% in Q1 2026, buying an estimated $12.7M and bringing the position to 125,348 shares worth $23.7M. The position accounts for 0.01% of the portfolio, ranked #975.

Citigroup first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $24.7M in Q3 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Citigroup held 125,348 shares of Jazz Pharmaceuticals worth $23.7M as of Q1 2026.
  • Citigroup bought 72,543 Jazz Pharmaceuticals shares in Q1 2026, an estimated $12.7M.
  • Jazz Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #975 holding.
  • Citigroup first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Jazz Pharmaceuticals position peaked at $24.7M in Q3 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.